First-line Treatment of Metastatic Disease
- 1 April 2015
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 29 (2) , 329-340
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group (GETUG V01)European Urology, 2011
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based ChemotherapyJournal of Clinical Oncology, 2011
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinomaAnnals of Oncology, 2011
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapyThe Lancet Oncology, 2011
- Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladderCancer, 2006
- Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive GeriatricOncology, 2004
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000
- Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of TherapyJournal of Clinical Oncology, 1999
- Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxelUrology, 1998
- Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.Journal of Clinical Oncology, 1997